US4681930A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Immune interferon and a method for its extraction and purification
Assignee: Takeda Pharmaceutical Co Ltd
•
Filing: 1984-08-10
•
Granted: 1987-07-21
•
Expires: 2004-08-10
Abstract
Abstract An intact human immune interferon protein and a method for the extraction and purification of intact recombinant human immune interferon is disclosed. This method permits the purification to homogenity of intact recombinant human immune interferon.
Inventors
- 👤 Hsiang-Fu Kung
- 👤 Hiromu Sugino
- 👤 Susumu Honda
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 18:27
CPC Classifications
C; C07; C07K; C07K1/00; C07K1/107; C07K1/113; C07K1/1136; C07K14/00; C07K14/435; C07K14/52; C07K14/555; C07K14/57; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S435/00; Y10S435/811; Y10S930/00; Y10S930/01; Y10S930/14; Y10S930/142
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
62 words
A method for the purification of intact recombinant human immune interferon protein from transformed microorganisms containing this protein comprising extracting the intact recombinant human immune interferon from said transformed microorganisms with a protease inhibitor compound and purifying the resulting intact recombinant human immune interferon from the extraction preparation with the use of monoclonal antibodies specific for the carboxyl terminus of said interferon.
Claim 2
Independent Claim
62 words
A method for the purification of intact recombinant human immune interferon protein from transformed microorganisms containing this protein comprising extracting the intact recombinant human immune interferon from said transformed microorganisms with a protease inhibitor compound and purifying the resulting intact recombinant human immune interferon from the extraction preparation with the use of monoclonal antibodies specific for the carboxyl terminus of said interferon.
Claim 3
Dependent Claim
13 words
The method of claim 1 wherein the protease inhibitor is a guanidinium salt.
Claim 4
Dependent Claim
11 words
The method of claim 2 wherein the protease inhibitor is guanidine-HCl.
Claim 5
Dependent Claim
12 words
The method of claim 2 wherein the guanidinium salt is in solution.
Claim 6
Dependent Claim
16 words
The method of claim 1 wherein the transformed microorganisms are suspended in a solution of guanidine-HCl.
Claim 7
Dependent Claim
14 words
The method of claim 5 wherein the solution is from 3 to 7M guanidine-HCl.
Claim 8
Dependent Claim
25 words
The method of claim 4 wherein there are from about 3 to 9 volumes of the guanidinium salt solution for every gram of transformed microorganism.
Claim 9
Dependent Claim
22 words
The method of claim 1 wherein the intact mature recombinant human immune interferon protein has a molecular weight of about 18,000 daltons.
Claim 10
Dependent Claim
28 words
The method of claim 1 in which the monoclonal antibodies are specific for an amino acid sequence comprising the sixteen carboxy terminal amino acid residues of the interferon.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-07-20 | 1991-01-19 | 1991-07-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-07-20 | 1995-01-19 | 1995-07-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-07-20 | 1999-01-19 | 1999-07-21 | $7700.00 | Window Closed / Lapsed |